CANbridge Pharmaceuticals Inc. - B (CANBRIDGE-B, 1228.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: 2.590 HKD
- Day Change: -0.020 (-0.77%)
- Open: 2.640 HKD
- High: 2.640 HKD
- Low: 2.550 HKD
- Previous Close: 2.610 HKD
- Volume: 147.00 K
- Market Cap: 1.32 B
- P/E Ratio: N/A
- Dividend Yield: N/A
- Board Lot: 1,000
- ISIN: KYG1821D1097
- Industry: Healthcare - Pharmaceuticals & Biotechnology
Company Overview
CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company. It is focused on research, development and commercialization of transformative therapies for rare disease. It has a drug portfolio, with three approved drugs and a pipeline of eight assets, targeting rare disease indications that have unmet needs. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. Its pipeline includes Hunterase, Livmarli, CAN106, and CAN103. Hunterase is an enzyme replacement therapy for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Livmarli an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter that is under development to treat rare cholestatic liver diseases including Alagille syndrome and progressive familial intrahepatic cholestasis.
Risk & Return Metrics
Based on 490 trading days of close price data (daily returns, annualized using 252 trading days).
| Metric | Daily | Annualized |
|---|---|---|
| Expected Return | 0.7855% | 618.23% |
| Risk (Std Dev) | 8.6491% | 137.30% |
| Metric | Value |
|---|---|
| First Price (HKD) | 0.305 |
| Last Price (HKD) | 2.610 |
| Total Return | 755.74% |